Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 09, 2023

SELL
$0.57 - $0.99 $15,429 - $26,798
-27,069 Reduced 11.66%
205,032 $170,000
Q1 2023

May 12, 2023

SELL
$0.51 - $0.78 $26,296 - $40,218
-51,562 Reduced 18.18%
232,101 $139,000
Q4 2022

Feb 09, 2023

SELL
$0.47 - $17.22 $6,114 - $224,032
-13,010 Reduced 4.39%
283,663 $156,000
Q3 2022

Nov 09, 2022

BUY
$0.74 - $15.01 $13,656 - $277,009
18,455 Added 6.63%
296,673 $208,000
Q2 2022

Aug 11, 2022

BUY
$0.71 - $2.43 $86,718 - $296,797
122,139 Added 78.25%
278,218 $274,000
Q1 2022

May 12, 2022

BUY
$2.31 - $5.13 $138,103 - $306,697
59,785 Added 62.09%
156,079 $371,000
Q4 2021

Feb 11, 2022

BUY
$4.45 - $8.09 $223,163 - $405,705
50,149 Added 108.68%
96,294 $458,000
Q3 2021

Nov 12, 2021

SELL
$6.94 - $8.85 $1.07 Million - $1.36 Million
-154,066 Reduced 76.95%
46,145 $361,000
Q2 2021

Aug 10, 2021

SELL
$7.45 - $16.27 $197,052 - $430,341
-26,450 Reduced 11.67%
200,211 $1.62 Million
Q1 2021

May 12, 2021

BUY
$8.78 - $12.8 $787,214 - $1.15 Million
89,660 Added 65.44%
226,661 $2.57 Million
Q4 2020

Feb 10, 2021

BUY
$1.08 - $8.2 $147,961 - $1.12 Million
137,001 New
137,001 $1.12 Million
Q3 2020

Nov 12, 2020

SELL
$0.95 - $1.42 $2,382 - $3,561
-2,508 Closed
0 $0
Q2 2020

Aug 13, 2020

SELL
$0.63 - $1.7 $2,765 - $7,461
-4,389 Reduced 63.64%
2,508 $3,000
Q1 2020

May 13, 2020

SELL
$0.67 - $1.85 $12,122 - $33,472
-18,093 Reduced 72.4%
6,897 $5,000
Q4 2019

Feb 10, 2020

SELL
$1.36 - $2.44 $9,996 - $17,934
-7,350 Reduced 22.73%
24,990 $42,000
Q3 2019

Nov 12, 2019

BUY
$1.74 - $2.83 $56,271 - $91,522
32,340 New
32,340 $72,000
Q3 2018

Nov 08, 2018

SELL
$1.38 - $1.94 $220 - $310
-160 Closed
0 $0
Q2 2018

Aug 14, 2018

BUY
$1.73 - $3.35 $276 - $536
160 New
160 $0

About CURIS INC


  • Ticker CRIS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 91,814,704
  • Market Cap $393M
  • Description
  • Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule drug candidate, which is in a Phase 1/2 clinical trial for the treatment of non-hodgkin lymphomas, and acute myel...
More about CRIS
Track This Portfolio

Track Group One Trading, L.P. Portfolio

Follow Group One Trading, L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Group One Trading, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Group One Trading, L.P. with notifications on news.